midazolam has been researched along with simvastatin in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (29.17) | 29.6817 |
| 2010's | 14 (58.33) | 24.3611 |
| 2020's | 3 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brucker, MJ; Gagliano, K; Gillen, L; Greenberg, HE; McLoughlin, D; Prueksaritanont, T; Rogers, JD; Vega, JM; Waldman, SA; Wong, PH | 1 |
| Bertino, JS; Chung, E; Kazierad, DJ; Nafziger, AN | 1 |
| Inui, N; Kagawa, Y; Kokudai, M; Sakaeda, T; Takeuchi, K; Watanabe, H | 1 |
| Hayashi, M; Shou, M; Skiles, GL; Xu, Y; Zhou, Y | 1 |
| Krishna, G; Ma, L; Martinho, M; Moton, A; O'Mara, E; Prasad, P | 1 |
| Alessi, F; Dingemanse, J; Hoch, M; Hoever, P; Theodor, R | 1 |
| Giroli, M; Kawabe, K; Misaka, S; Onoue, S; Watanabe, H; Werba, JP; Yamada, S | 1 |
| Liu, L; Liu, X; Sai, Y; Wang, D; Wang, J; Xia, S; Xue, W | 1 |
| Burhenne, J; Haefeli, WE; Lausecker, B; Mikus, G; Stoll, F; Thomsen, T; Weiss, J | 1 |
| Cannady, EA; Friedrich, S; Krueger, KA; Nicholls, SJ; Rehmel, JR; Suico, JG; Wang, MD | 1 |
| Ducray, PS; Endo-Tsukude, C; Gardner, I; Gill, KL; Hatley, OJ; Machavaram, KK; Parrott, N; Terao, K | 1 |
| Chinn, LW; Durk, MR; Jones, NS; Kenny, JR; Salphati, L; Yoshida, K | 1 |
| Fujita, T; Huang, J; Kawai, M; Kumagai, Y; Maeda, M; Nagaoka, M; Sasaki, Y; Takenaka, T | 1 |
| Gardner, I; Hatley, O; Jamei, M; Johnson, TN; Small, BG | 1 |
1 review(s) available for midazolam and simvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
9 trial(s) available for midazolam and simvastatin
| Article | Year |
|---|---|
Simvastatin does not affect CYP3A activity, quantified by the erythromycin breath test and oral midazolam pharmacokinetics, in healthy male subjects.
Topics: Administration, Oral; Adult; Aryl Hydrocarbon Hydroxylases; Breath Tests; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Erythromycin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Midazolam; Oxidoreductases, N-Demethylating; Simvastatin; Single-Blind Method | 2000 |
Comparison of midazolam and simvastatin as cytochrome P450 3A probes.
Topics: Administration, Oral; Adult; Anesthetics, Intravenous; Anticholesteremic Agents; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP3A; Female; Humans; Male; Midazolam; Simvastatin | 2006 |
Effects of statins on the pharmacokinetics of midazolam in healthy volunteers.
Topics: Adult; Area Under Curve; Atorvastatin; Cross-Over Studies; Cytochrome P-450 CYP3A; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypnotics and Sedatives; Japan; Male; Midazolam; Pyrroles; Quinolines; Simvastatin | 2009 |
Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Humans; Male; Midazolam; Middle Aged; Simvastatin; Triazoles; Young Adult | 2012 |
Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.
Topics: Acetamides; Administration, Oral; Adult; Analysis of Variance; Area Under Curve; Biotransformation; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Drug Interactions; Enzyme Inhibitors; Germany; Half-Life; Humans; Hydrocortisone; Hydroxylation; Isoquinolines; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Simvastatin; Substrate Specificity; Young Adult | 2013 |
Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity.
Topics: Adult; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Enzyme Inhibitors; Female; Humans; Male; Midazolam; Middle Aged; Ritonavir; Simvastatin | 2013 |
CYP-mediated drug-drug interactions with evacetrapib, an investigational CETP inhibitor: in vitro prediction and clinical outcome.
Topics: Anticholesteremic Agents; Benzodiazepines; Cells, Cultured; Cholesterol Ester Transfer Proteins; Cytochrome P-450 CYP3A Inhibitors; Double-Blind Method; Drug Interactions; Humans; Microsomes, Liver; Midazolam; Simvastatin; Tolbutamide | 2015 |
Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI.
Topics: Adult; Area Under Curve; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biomarkers; Cytochrome P-450 CYP3A; Drug Interactions; Female; Humans; Liver-Specific Organic Anion Transporter 1; Male; Midazolam; Middle Aged; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Pyridones; Rosuvastatin Calcium; Simvastatin; Young Adult | 2020 |
A Drug-Drug Interaction Study to Evaluate the Effect of TAS-303 on CYP3A Activity in the Small Intestine and Liver.
Topics: Administration, Intravenous; Administration, Oral; Adrenergic Uptake Inhibitors; Adult; Anesthetics, Intravenous; Anticholesteremic Agents; Area Under Curve; Computer Simulation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Healthy Volunteers; Humans; Intestine, Small; Liver; Male; Midazolam; Models, Biological; Simvastatin; Young Adult | 2020 |
14 other study(ies) available for midazolam and simvastatin
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs.
Topics: Area Under Curve; Carbamazepine; Cytochrome P-450 CYP3A; Drug Interactions; Enzyme Induction; Hepatocytes; Humans; Midazolam; Nifedipine; Phenobarbital; Rifampin; Simvastatin; Substrate Specificity | 2011 |
Green tea extract affects the cytochrome P450 3A activity and pharmacokinetics of simvastatin in rats.
Topics: Animals; Camellia sinensis; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Female; Microsomes, Liver; Midazolam; Plant Extracts; Rats; Simvastatin; Troleandomycin | 2013 |
A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human.
Topics: Calcium Channel Blockers; Cyclosporine; Cytochrome P-450 CYP3A; Drug Interactions; Gastric Mucosa; Humans; Intestine, Small; Liver; Microsomes, Liver; Midazolam; Models, Biological; Simvastatin; Stereoisomerism; Verapamil | 2013 |
Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations.
Topics: Administration, Oral; Adult; Caffeine; Clinical Trials as Topic; Computer Simulation; Cytochrome P-450 Enzyme System; Dextromethorphan; Down-Regulation; Drug Development; Drug Interactions; Female; Humans; Interleukin-6; Male; Midazolam; Middle Aged; Models, Biological; Neuromyelitis Optica; Omeprazole; Rare Diseases; Serum Albumin, Human; Simvastatin; Warfarin | 2019 |
Incorporation and Performance Verification of Hepatic Portal Blood Flow Shunting in Minimal and Full PBPK Models of Liver Cirrhosis.
Topics: Buspirone; Humans; Liver Cirrhosis; Midazolam; Models, Biological; Propranolol; Simvastatin | 2023 |